SNS-314 CAS:1146618-41-8

CAS NO: 1146618-41-8
SNS-314 CAS:1146618-41-8
Description Review
Description

SNS 314 mesylate is a small molecule inhibitor of Aurora kinase A and B, which are enzymes involved in the regulation of cell division. Aurora kinases play an important role in the progression of cancer by promoting tumor growth and metastasis. SNS 314 mesylate inhibits Aurora kinase activity, potentially slowing or stopping the proliferation of cancer cells. The chemical name of SNS 314 mesylate is (R)-N-(4-(2-((3-chloro-2-(pyridin-2-yl)phenyl)amino)-5-methylpyrimidin-4-yl)piperazin-1-yl)propionamide methanesulfonate, and its molecular formula is C25H28ClN7O3S.CH4O3S. Its formula weight is 645.18 g/mol, and its CAS number is 1146618-41-8.

Top ten keywords related to SNS 314 mesylate according to Google searches are:

  1. Aurora kinase inhibitor
  2. Cancer treatment
  3. Cell division
  4. Metastasis
  5. Small molecule inhibitor
  6. Anti-tumor
  7. Non-Hodgkin lymphoma
  8. Chemotherapy
  9. Glioblastoma
  10. Tyrosine kinase inhibitor

Synonyms for SNS 314 mesylate include N-[4-[2-[3-chloro-2-(pyridin-2-yl)phenyl]amino]-5-methylpyrimidin-4-yl]piperazin-1-yl]propanamide methanesulfonate, SNS-314, and SNS314.

Health benefits of SNS 314 mesylate:

SNS 314 mesylate's potential health benefits lie in its ability to inhibit Aurora kinases A and B, both of which play a role in cancer growth and metastasis. SNS 314 mesylate has shown promise in preclinical studies as a potential treatment for various types of cancer, including glioblastoma and non-Hodgkin lymphoma.

Potential effects:

Preclinical studies have demonstrated that SNS 314 mesylate can induce cell cycle arrest and apoptosis in cancer cells. Additionally, it has been suggested that inhibition of Aurora kinases may sensitize cancer cells to chemotherapy, making them more susceptible to traditional cancer treatments.

Product mechanism:

SNS 314 mesylate inhibits Aurora kinases A and B, leading to the disruption of proper cell division and potentially inducing apoptosis in cancer cells. In addition, inhibition of Aurora kinases may also affect cellular signaling pathways involved in cell survival and proliferation.

Safety:

While SNS 314 mesylate has shown promise in preclinical studies, there is still much research to be done before it can be considered safe for human use. Some studies have noted potential toxicity to normal cells, and more research is needed to determine the safety profile of this compound.

Side effects:

As with any medication or potential treatment, there is always the possibility of side effects. Preclinical studies of SNS 314 mesylate have noted potential gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. Additional side effects may include fatigue, headache, and respiratory infections.

Dosing information:

Currently, there is no established dosing information for SNS 314 mesylate in humans, as it is still in the early stages of development. However, preclinical studies have provided some insight into the optimal dosing regimen for use in animal models, which may guide future clinical trials.

Conclusion:

SNS 314 mesylate has shown promise as a potential treatment for various types of cancer due to its ability to inhibit Aurora kinases A and B. While much more research is needed before it can be considered safe for human use, preclinical studies have provided valuable insight into the potential therapeutic applications of this compound. Further research will be necessary to establish its safety profile, determine appropriate dosing regimens, and assess its potential for use in various cancer types

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code